December 30, 2024Nature CommunicationsOpen Access

An adenosine analog shows high antiviral potency against coronavirus and arenavirus mainly through an unusual base pairing mode

View Full Paper

Ask AI

Bookmark

Why the study?

Most ribose-modified nucleoside analogs lack broad-spectrum activity against RNA viruses, likely due to differences in ribose-RdRP interactions across virus families.

Population

SARS-CoV-2-infected K18-human ACE2 mice and viral RdRP-RNA complexes

Comparison

HNC-1664 treatment

Design

Preclinical laboratory and animal study

Authors

XJXuping JingChinese Academy of Sciences MLMing LiLiaocheng University MGMinli GaoChinese Academy of Sciences

Discussion

Member takes

Implication

Should not yet change practice; leaves open whether this unusual pairing yields a translatable broad-spectrum antiviral.

Structured PICO

Population

In vitro cell lines (Vero E6, Caco-2, Huh-7, RD) and K18-hACE2 transgenic mice infected with SARS-CoV-2 delta strain (n=19 mice total).

Intervention

HNC-1664 (adenosine analog) 50 mg/kg oral gavage twice daily (in vivo) or various concentrations (in vitro)

Comparator

Vehicle control; Molnupiravir 500 mg/kg oral gavage twice daily (in vivo); Remdesivir (in vitro)

Outcome

Viral replication (IC50, viral titer, viral gene copies) and mouse survival at 4 days post-infectionsurrogate

HNC-1664 demonstrates broad-spectrum antiviral activity against coronaviruses and arenaviruses by non-catalytically blocking RNA synthesis through an alternative base pairing strategy.

Cite This Study

Jing et al. (2024) studied this question.

synapsesocial.com/papers/6a7f4f62aa1ae1567cb3d77e https://doi.org/10.1038/s41467-024-54918-3

View Full Paper

Ask AI

Bookmark

December 30, 2024Nature CommunicationsOpen Access

An adenosine analog shows high antiviral potency against coronavirus and arenavirus mainly through an unusual base pairing mode

View Full Paper

Ask AI

Bookmark

Why the study?

Most ribose-modified nucleoside analogs lack broad-spectrum activity against RNA viruses, likely due to differences in ribose-RdRP interactions across virus families.

Population

SARS-CoV-2-infected K18-human ACE2 mice and viral RdRP-RNA complexes

Comparison

HNC-1664 treatment

Design

Preclinical laboratory and animal study

Authors

XJXuping JingChinese Academy of Sciences MLMing LiLiaocheng University MGMinli GaoChinese Academy of Sciences

Discussion

Member takes

Implication

Should not yet change practice; leaves open whether this unusual pairing yields a translatable broad-spectrum antiviral.

Structured PICO

Population

In vitro cell lines (Vero E6, Caco-2, Huh-7, RD) and K18-hACE2 transgenic mice infected with SARS-CoV-2 delta strain (n=19 mice total).

Intervention

HNC-1664 (adenosine analog) 50 mg/kg oral gavage twice daily (in vivo) or various concentrations (in vitro)

Comparator

Vehicle control; Molnupiravir 500 mg/kg oral gavage twice daily (in vivo); Remdesivir (in vitro)

Outcome

Viral replication (IC50, viral titer, viral gene copies) and mouse survival at 4 days post-infectionsurrogate

HNC-1664 demonstrates broad-spectrum antiviral activity against coronaviruses and arenaviruses by non-catalytically blocking RNA synthesis through an alternative base pairing strategy.

Cite This Study

Jing et al. (2024) studied this question.

synapsesocial.com/papers/6a7f4f62aa1ae1567cb3d77e https://doi.org/10.1038/s41467-024-54918-3

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark